![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 9
Zeitschriftenartikel
Seiler, T. und Dreyling, M.
(2017):
Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
In: Expert Opinion On investigational Drugs, Bd. 26, Nr. 8: S. 909-915
Cramer, P.; Tresckow, J. von; Bahlo, J.; Robrecht, S.; Al Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.-M.; Fischer, K.; Seiler, T.; Fischer von Weikersthal, L.; Hebart, H.; Kreuzer, K.-A.; Ritgen, M.; Kneba, M.; Wendtner, C.-M.; Stilgenbauer, S.; Eichhorst, B. und Hallek, M.
(2017):
BENDAMUSTINE (B), followed by OBINUTUZUMAB (G, GA101) and VENETOCLAX (A, ABT-199) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG PHASE-II-TRIAL of the German CLL Study Group (GCLLSG).
In: Hämatologica, Bd. 102: S. 171-172
Al-Sawaf, O.; Robrecht, S.; Bahlo, J.; Fink, A. M.; Cramer, P.; Tresckow, J. von; Maurer, C.; Bergmann, M.; Seiler, T.; Lange, E.; Kneba, M.; Stilgenbauer, S.; Döhner, H.; Kiehl, M. G.; Jäger, U.; Wendtner, C. M.; Fischer, K.; Göde, V.; Hallek, M.; Eichhorst, B. und Hopfinger, G.
(2017):
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
In: Leukemia, Bd. 31, Nr. 10: S. 2251-2253
Cramer, P.; Tresckow, J. von; Bahlo, J.; Robrecht, S.; Al-Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.-M.; Fischer, K.; Tausch, E.; Seiler, T.; Fischer von Weikersthal, L.; Hebart, H.; Kreuzer, K.-A.; Ritgen, M.; Kneba, M.; Wendtner, C.-M.; Stilgenbauer, S.; Eichhorst, B. und Hallek, M.
(2017):
Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG).
In: Oncology Research and Treatment, Bd. 40: S. 24
Maurer, C.; Langerbeins, P.; Bahlo, J.; Cramer, P.; Fink, A. M.; Pflug, N.; Engelke, A.; Tresckow, J. von; Kovacs, G.; Stilgenbauer, S.; Wendtner, C.-M.; Müller, L.; Ritgen, M.; Seiler, T.; Fischer, K.; Hallek, M. und Eichhorst, B.
(2016):
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
In: Leukemia, Bd. 30, Nr. 10: S. 2019-2025
Estenfelder, S.; Tausch, E.; Huber, H.; Bloehdorn, J.; Cymbalista, F.; Leblond, V.; Delmer, A.; Ibach, S.; Choquet, S.; Dartigeas, C.; Cazin, B.; Tournilhac, O.; Pegourie, B.; Seiler, T.; Sökler, M.; Zirlik, K.; Alt, J.; Schetelig, J.; Hallek, M.; Dreger, P.; Döhner, H. und Stilgenbauer, S.
(2016):
Mutation analysis by targeted next generation sequencing in ultra high risk CLL patients treated within the CLL20 study.
In: Haematologica, Bd. 101: S. 228-229
Herold, Tobias; Mulaw, M. A.; Jurinovic, Vindi; Seiler, T.; Metzeler, Klaus H.; Dufour, A.; Schneider, S.; Kakadia, P. M.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C.; Dreyling, Martin und Bohlander, Stefan K.
(2012):
High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.
In: Leukemia & Lymphoma, Bd. 54, Nr. 8: S. 1652-1657
Herold, Tobias; Jurinovic, Vindi; Metzeler, Klaus H.; Boulesteix, Anne-Laure; Bergmann, M.; Seiler, T.; Mulaw, M.; Thoene, S.; Dufour, A.; Pasalic, Z.; Schmidberger, Markus; Schmidt, M.; Schneider, S.; Kakadia, P. M.; Feuring-Buske, M.; Braess, J.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K.
(2011):
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia.
In: Leukemia, Bd. 25, Nr. 10: S. 1639-1645
Herold, Tobias; Jurinovic, Vindi; Mulaw, M.; Seiler, T.; Dufour, A.; Schneider, S.; Kakadia, P. M.; Feuring-Buske, M.; Braess, J.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K.
(2011):
Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20.
In: Genes, Chromosomes and Cancer, Bd. 50, Nr. 7: S. 546-558